Mary Riley, DO
Internal Medicine · Uniontown, PANPI 1982055646
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,397 of the $4,258 with a category attached, or 79.8%. 24 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 31.7% of the total. Reporting peaked in 2023 at $2,111 and has fallen 54.7% since, to $956 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- AstraZeneca$573
- Pfizer$470
- Novo Nordisk$357
- AbbVie$251
- Lilly USA, LLC$227
- plus $1K from 18 others
Across 4 payments — averaging $82,644 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$331K
What the payments were for
- Travel & lodging$86120%
- Food & beverage$3,39780%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,351 |
| AstraZeneca | 21 | $573 |
| Pfizer | 24 | $470 |
| Novo Nordisk | 21 | $357 |
| AbbVie | 22 | $251 |
| Lilly USA, LLC | 14 | $227 |
| Abbott | 11 | $191 |
| Johnson & Johnson | 8 | $121 |
| E.r. Squibb & Sons, L.L.C. | 6 | $112 |
| GSK | 6 | $108 |
| Bayer | 5 | $82 |
| Amgen | 4 | $78 |
| Dexcom, Inc. | 4 | $57 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Astellas Pharma US Inc | 2 | $38 |
| Shield Therapeutics Inc | 2 | $37 |
| Merck | 2 | $35 |
| Boehringer Ingelheim | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Medicomp Inc | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,258 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $90,172 |
| JardianceEmpagliflozin | 74 | $81,316 |
| OzempicSemaglutide | 38 | $44,583 |
| MounjaroTirzepatide | 25 | $38,498 |
| XareltoRivaroxaban | 40 | $22,829 |
| JanuviaSitagliptin Phosphate | 14 | $19,032 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,730 |
| EntrestoSacubitril/Valsartan | 17 | $11,613 |
| Rosuvastatin Calcium | 96 | $3,203 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,797 |
| LantusInsulin Glargine,hum.Rec.Anlog | 12 | $2,150 |
| Atorvastatin Calcium | 168 | $1,895 |
| Levothyroxine Sodium | 213 | $1,825 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $1,794 |
| Pantoprazole Sodium | 177 | $1,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $470 | $90,172134 claims |
| Boehringer IngelheimJardiance | $25 | $81,31674 claims |
| Novo NordiskOzempic | $357 | $44,58338 claims |
| Lilly USA, LLCMounjaro | $227 | $38,49825 claims |
| Johnson & JohnsonXarelto | $121 | $22,82940 claims |
| MerckJanuvia | $35 | $19,03214 claims |
| GSKTrelegy Ellipta | $108 | $11,73019 claims |
| Sanofi-aventis U.S. LLCLantus | $16 | $2,15012 claims |
| AbbVieSynthroid | $251 | $1,42616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Uniontown
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.